Back to dashboard
All PlansCoverageMedium impact

Irreversible Electroporation of Tumors Located in the Liver, Pancreas, Kidney, Lung, or Prostate

Blue Cross & Blue Shield of Mississippi·MS · Oncology, General Surgery, Urology +3 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply

Summary

BCBSMS has updated their medical policy on Irreversible Electroporation (IRE) for tumor treatment in liver, pancreas, kidney, lung, and prostate. The policy provides detailed coverage criteria and clinical background for this specialized ablation technique that uses electric pulses to destroy cancer cells without thermal damage.

Action Required

Action needed
Review the updated IRE policy to understand coverage criteria for tumor ablation procedures in liver, pancreas, kidney, lung, and prostate. Ensure documentation supports medical necessity when submitting claims for IRE procedures, particularly noting the policy's emphasis on cases where patients are not candidates for surgery or traditional thermal ablation methods.